Filana Therapeutics reports 2025 net loss of $91M; cash burn guidance and TSC program clinical hold detailed

FILANA THERAPEUTICS, INC.

Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.
Est. cash at June 30, 2026 at $47-50M; net cash use H1 2026 $14-17M plus $31.25M litigation settlement payment.
R&D expenses fell 62% to $26.6M after Alzheimer's program phase-out; TSC program on clinical hold since Dec 2025.
G&A expenses $68.8M include $31.3M securities litigation contingency; no insurance recoveries.
Name change to Filana Therapeutics reflects focus on filamin A modulation for TSC-related epilepsy.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FILANA THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss for 2025 was $91.0 million, EPS $1.88 per share.

Period: the fourth quarter and year ended December 31, 2025
Net income: Net loss for 2025 was $91.0 million
EPS: $1.88 per share
Result: reported results

Exact text from the filing

Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

View on SEC.gov

308 earnings releases filed in the last 30 days. Browse all earnings releases →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001171843-26-001506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.